Treatment of Cancer in Conjunction with Other Agents

Anticancer Therapeutics

Volumn , Issue , 2008, Pages 349-364

  Smith, Gary Robert ^a  

^a Perses Biosystems Ltd   (United Kingdom)

Author keywords

Agency for healthcare research and quality (AHRQ); Ang II and AT1 receptor expression; Angiotensin II (Ang II) peptide hormone; AT1 receptor expression and increased invasiveness; Cancer progression suppression mechanisms; Cancer treatment and other agents; Helicobacter pylori and chronic inflammation; Non steroidal anti inflammatory drug (NSAID)

Indexed keywords

EID: 77649317459     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470697047.ch19     Document Type: Chapter

References (34)

1. US Preventive Services Task Force recommendation statement. Routine aspirin or nonsteroidal antiinflammatory drugs for the primary prevention of colorectal cancer. Ann Intern Med 2007, 146(5), 361-4.
2. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003, 21(14), 2645-50.
3. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001, 357(9255), 539-45.
4. Brown MJ, Mackenzie IS, Ashby MJ, Balan KK, Appleton DS. AT2 receptor stimulation may halt progression of pheochromocytoma. Ann N Y Acad Sci 2006, 1073, 436-43.
5. Chan AT, Ogino S, Fuchs CS, et al. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007, 356(21), 2131-42.
6. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005, 16(7), 293-9.
7. Ferrari V, Valcamonico F, Amoroso V, et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.' Cancer Chemother Pharmacol 2006a, 57(2), 185-90.
8. Ferreri AJ, Ponzoni M, Guioboni M, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst 2006b, 98(19), 1375-82.
9. Gradilone A, Pulcinelli FM, Lotti LV, Martino S, Mattiello T, Frati L, Agliano AM, Gazzaniga P. Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications. J Clin Oncol 2007, 25(27), 4318-20; author reply 4320.
10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1), 57-70.
11. Ino K Shibata K, Kajiyama, Yamamoto E, Nagasaka T, Nawa A, Nomura S, Kikkawa F. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer 2006, 94(4): 552-60.
12. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007, 99(8), 608-15.
13. Khor LY, Bae K, Pollack A, et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 2007, 8(10), 912-20.
14. Kikkawa F, Mizuno M, Shibata K, Kajiyama H, Morita T, Ino K, Nomura S, Mizutani S. Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am J Obstet Gynecol 2004, 190(5), 1258-63.
15. Lilenbaum R, Socinski MA, Altorki LK, et al. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 2006, 24(30), 4825-32.
16. Mann JR, Backlund MG, DuBois RN, et al. Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005, 2(4), 202-10.
17. McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005, (1), CD005180.
18. Reckamp KL, Krysan K, Morrow JD, et al. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 2006, 12(11 Pt 1), 3381-8.
19. Rocken C, Rohl FW, Diebler E, Lendeckel U, Pross M, Carl-McGrath S, Ebert MP. The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(6), 1206-12.
20. Rocken C, Neumann K, Carl-McGrath S, et al. The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients. Neoplasia 2007b, 9(9), 716-22.
21. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005, 16(10): 3038-45.
22. Shibata K, Kikkawa F, Mizokami Y, Kajiyama H, Ino K, Nomura S, Mizutani S. Possible involvement of adipocyte-derived leucine aminopeptidase via angiotensin II in endometrial carcinoma. Tumour Biol 2005, 26(1), 9-16.
23. Simmons DL, Botting RM, Hla T, et al. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004, 56(3), 387-437.
24. Slaviero KA, Clarke SJ, Rivory LP, et al. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy.' Lancet Oncol 2003, 4(4), 224-32.
25. Smith GR, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond) 2004, 1(1), 3.
26. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003, 35(6), 881-900.
27. Uemura H, Hasumi H, Kawahara T, et al. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 2005, 10(6), 405-10.
28. Ulrich CM, Bigler J, Potter JD, et al. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006, 6(2), 130-40.
29. Vairaktaris E, Yapijakis C, Tsigris C, et al. Association of angiotensin-converting enzyme gene insertion/ deletion polymorphism with increased risk for oral cancer. Acta Oncol 2007, 46(8), 1097-102.
30. Weinberg AJ, Zappe DH, Ramadugu R, Weinberg MS. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease. J Hypertens Suppl 2006, 24(1), S95-9.
31. Woetmann A, Lovato P, Eriksen KW, et al. Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood 2007, 109(8), 3325-32.
32. Yaren A, Turgut S, Kursunluoglu R, Oztop I, Turgut G, Degirmencioglu S, Kelten C, and Erdem E. Insertion/deletion polymorphism of the Angiotensin I-converting enzyme gene in patients with breast cancer and effects on prognostic factors. J Invest Med 2007, 55(5), 255-61.
33. Yigit B, Bozkurt N, Narter F, Yilmaz H, Yucebas E, Isbir T. Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis.' Anticancer Res 2007, 27(2), 933-6.
34. Zhao W, Diz DI, Robbins ME, et al. Oxidative damage pathways in relation to normal tissue injury.' Br J Radiol 2007, 80 Spec No 1, S23-31.